Search
Analyst Tuesdays: Mizuho Senior Analyst Graig Suvannavejh shares his take on the difficult biotech environment and discusses upcoming clinical trail catalysts for companies he covers
He sets the table for upcoming readouts from Axsome, Vigil Neuro, Verastem, Corvus, and Harmony Biosciences.
Mar 18
From struggling with sickle cell disease to climbing mountains - a firsthand account of how gene therapy has been life changing
Jimi Olaghere describes how his life has changed after participating in a clinical trial for the CRISPR based gene therapy for sickle...
Mar 14
Alta Partners' Managing Director Bob More shares his take on biotech and his philosophy of investing in people - from the Timmerman Report 10th Anniversary Celebration in Seattle
He discusses the current downturn, they key of being focused, and his preference of investing in people first. Plus, comments on...
Mar 13
Congratulations to Luke Timmerman on 10 years of Timmerman Report. We salute you!
Celebrating with the Seattle (and beyond) biotech community.
Mar 13
Tour of Scotland: Scotland's Chief Scientist (Health) describes how new technologies are being embraced in the NHS, and why Scotland is a good place for global companies to run clinical trials
Professor Dame Anna Dominiczak describes how new technologies are being rolled out in the community equitably, such as digital...
Mar 13
Tour of Scotland: Mark Cook, Co-Chair of Life Sciences Scotland, describes the importance of life sciences to the area and what the government and industry are doing to support it
He describes the assets that Scotland has to offer the industry such as excellent universities that derive innovation and a diverse...
Mar 13
Tour of Scotland: Vicki Hazley, Associate Director of The Scottish National Investment Bank, discusses how The Bank invests in life sciences
She describes The Bank's goal of supporting life sciences in Scotland and making a societal impact, how it aims to co-invest with...
Mar 13
Tour of Scotland: A leading investor who is focused on life sciences in Scotland shares his thoughts on the innovation happening in the area
Andrew McNeill, Managing Partner of St. Andrews based Eos Advisory, introduces us to the firm and some portfolio companies including...
Mar 12
Tour of Scotland: University of Dundee has established a world-class Centre for Protein Degradation, one of the hottest emerging modalities in biotech
Founder and Director Alessio Ciulli explains the science behind protein degradation. He then describes the facilities that have been...
Mar 11
Tour of Scotland: The Head of Business Development at University of Dundee's Drug Discovery Unit talks about how the university helps biopharma companies translate science into medicines
Charlotte Green describes the work that the unit does in tropical diseases, CNS, women's health, and oncology. She also highlights their...
Mar 11
Tour of Scotland: Sir Michael Ferguson introduces the work in life sciences that has built up at The University of Dundee and the specialized centers that have come from it
He discusses speciality work relating to molecular cell biology / signal transduction, and translational science. Plus, the MRC Protein...
Mar 11
Analyst Thursdays: William Blair Senior Analyst Andy Hsieh talks about his new obesity sector report and the companies he initiated
He discusses what to look for in safety and efficacy, new targets, and his thoughts on the potential role of oral therapies. Plus,...
Mar 6
From Boston: Stifel Senior Analyst Paul Matteis talks about the orexin class of wakefulness medicines in development, and comments on recent news from companies he covers
He shares his take on biotech and discusses Alkermes, Tekada, Centessa, Jazz, Biogen, Stoke, Alnylam, BridgeBio, Xenon, and more.
Feb 24
Paula Brown Stafford, CEO of the global CRO Allucent, discusses how the company is purpose built to partner with mid-to-small sized biopharma companies on their success
She describes what appealed to her about Allucent when she took the CEO job in July of last year, and highlights the company's regulatory...
Feb 13
Welcoming Ryan Flinn as BiotechTV's new 'AI in Biotech' contributor
Ryan is based in the Bay Area, and will will be covering AI news there on the ground and virtually worldwide for BiotechTV.
Feb 13
Oppenheimer's Head of Healthcare Investment Banking shares his take on 2025 and highlights M&A, IPOs, and the ability of companies to raise money this year
Michael Margolis discusses the macro and policy factors that are in play this year, comments on the China factor, and describes how...
Feb 11
Mizuho Senior Biotech Analyst Salim Syed shares his take on 2025 and key catalysts from companies he covers
He discusses BridgeBio, Cytokinetics, Wave, Vaxcyte, Iovance, Unity, and Enliven
Feb 11
Dana-Farber Cancer Institute investigators describe a personalized cancer vaccine trial in kidney cancer that was published in Nature. All nine patients did not see their cancer recur.
Toni Choueiri and Patrick Ott describe how this peptide-based vaccine was peronalized to dozens of the patient's neoantigens in this this ad
Feb 6
SF Healthcare Week: Affinity Asset Advisors' Head of Research Patrick Nosker shares his take on Monday's conference news, and discusses some of his fund's top holdings
He talks about todays M&A heavy news and the market reaction to it, and comments on Xenon, Madrigal, Nurix, and Wave.
Jan 13
SF Healthcare Week: Flagship Pioneering's Noubar Afeyan on Moderna, gov't policy, China, and "polyintelligence" in drug development
He shares his thoughts on Moderna's transition, what policies he would like to see promoted in government, competing with China, and the...
Jan 13
.png){kind=logo}
